Integral estimate of the parameters of transrectal multifocal rebiopsy in the diagnosis of prostate cancer
https://doi.org/10.17650/1726-9776-2006-2-3-37-39
Abstract
Materials and Methods. The results of transrectal multifocal prostatic rebiopsy made under ultrasound guidance at the Clinic of Urology, Military Medical Academy, in 1998 to 2004 were studied.
A total of 2352 males were examined; of them, 125 patients underwent rebiopsy. The patients’ age was 54 to 87 years (mean age 60.3 years). The patients were divided into 4 age groups: 1) 51-60 years [11% (14/125)]; 2) 61-70 years [47% (59/125)]; 3) 71-80 years [35% (44/125)]; 4) > 81 years [0.3% (4/125)]. There were 6 to 14 biopsy probes.
Results. The study showed that rebiopsy of the prostate identified its cancer in 23% of the patients having a negative primary histological result. It was also established that the patients in whom primary biopsy revealed prostatic intraepithelial neoplasia (PIN) and/or an increase in PSA of > 0.75 ng/ml per year and its density > 0.15 ng/ml/cm3 should be referred to a repeated histological study within 6 to 12 months. When these rules were observed, there were the most favorable prognostic signs: no capsular invasion, lower Glisson scores, and none metastasis.
Conclusion. The study has provided the following indications for rebiopsy:
— a continually elevating PSA level or its preservation after primary negative biopsy;
— abnormal findings on rectal examination and transrectal ultrasound study;
— high-grade PIN in the prior biopsy specimen.
About the Authors
S. B. PetrovRussian Federation
Clinic of Urology
Ye. I. Veliyev
Russian Federation
Moscow
R. A. Yeloyev
Russian Federation
Clinic of Urology
I. S. Lysenko
Russian Federation
Clinic of Urology
References
1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 31: 8–31.
2. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М.; 1999. с. 5.
3. Djavan B., Zlotta A.R., Remzi M. et al. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1051 men. J Urol 2000; 163(4): 1144–8.
4. Seidman H., Mushinski M.H., Gelb S.K., Silverberg E. Probabilities of eventually developing or dying of cancer in United States 1985. CA Cancer J Clin 1985; 35: 36–56.
5. Morgan T.O., McLeod D.G., Leifer E.S. et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76–80.
6. Djavan B., Remzi M., Marberger M. When and how a prostatic rebiopsy should be performed? Eur Urol Suppl 2002;1 (6): 52–9.
7. Hendrikx A., Safarik L., Hammerer P. TRUS and biopsy: practical aspects. Eur Urol 2002; 41(6): 1–10.
8. Gretzer M.B., Partin A.W. PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl 2002; 1 (6): 21–7.
Review
For citations:
Petrov S.B., Veliyev Ye.I., Yeloyev R.A., Lysenko I.S. Integral estimate of the parameters of transrectal multifocal rebiopsy in the diagnosis of prostate cancer. Cancer Urology. 2006;2(3):37-39. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-3-37-39